NCRI Press Release, 9 November 2016
Date published: Apr 03 2018
Marker for aggressive prostate cancer doubles-up as a drug target
Download the attachmentRecent Tweets
-
94% of the delegates who attended last year's Conference would recommend it to a colleague. 👍 There is still time f… https://t.co/lKDy0Mnxhr
22 hours ago -
October is #BreastCancerAwareness Month! Many sessions at #NCRI2019 will use #breastcancerresearch as an exemplar… https://t.co/ZAOyqviM3N
2 days ago -
Have a look at what @plummer_ruth , co-chair of #NCRI2019, said about last year's Conference. Hurry up - standard… https://t.co/36SumSsOvK
3 days ago
- 19 Sep 2019Head of Business Operations (NCRI) vacancy
- 19 Jul 2019Consumer (Patient / Carers) vacancies for NCRI Groups available. Apply today!
- 18 Jun 2019Register now for the NCRI Annual Lymphoma UK Trials Meeting: 1 November 2019
- 20 May 2019Celebrating ten years of NCRI’s Clinical and Translational Radiotherapy Research Group
- 29 Apr 2019NCRI and The British Society for Immunology announce new partnership
- 14 Mar 2019Register now for the NCRI CTU Annual Trials Meeting: 17 June 2019
RSS Feed